{"id":36245,"date":"2025-06-30T14:58:06","date_gmt":"2025-06-30T06:58:06","guid":{"rendered":"https:\/\/flcube.com\/?p=36245"},"modified":"2025-06-30T14:58:07","modified_gmt":"2025-06-30T06:58:07","slug":"genfleet-therapeutics-files-for-hong-kong-ipo-amid-kras-inhibitor-success","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=36245","title":{"rendered":"GenFleet Therapeutics Files for Hong Kong IPO Amid KRAS Inhibitor Success"},"content":{"rendered":"\n<p>China-based GenFleet Therapeutics (Shanghai) Inc. has submitted its initial public offering (IPO) application to the Main Board of the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor.<\/p>\n\n\n\n<p><strong>Company Overview<\/strong><br>GenFleet is a clinical-stage biopharmaceutical company focused on developing novel drugs for oncology, autoimmune, and inflammatory diseases. It has established a pipeline of eight drug candidates, five of which are in clinical development, and three are in preclinical research.<\/p>\n\n\n\n<p><strong>Product Highlights<\/strong><br>Fulzerasib (GFH925), a selective KRAS G12C inhibitor, received approval in China in December 2023 for treating advanced non-small cell lung cancer (NSCLC) that has progressed after standard therapy. This makes it the first of its kind in China. GFH375, a small molecule KRAS G12D inhibitor, is currently undergoing Phase I\/II studies in China for advanced solid tumors with the KRAS G12D mutation.<\/p>\n\n\n\n<p><strong>Innovative Programs<\/strong><br>The company is advancing several novel-target programs, including GFS202A, a GDF15\/IL-6 bispecific antibody (BsAb), and GFH312, an RIPK1 kinase inhibitor. GFH312 has received approval for studies in peripheral artery disease and primary biliary cholangitis in the US and China.<\/p>\n\n\n\n<p><strong>Financial Performance<\/strong><br>In the first four months of this year, GenFleet reported revenues of RMB 82.15 million (USD 11.47 million) and a loss of RMB 66.62 million (USD 9.3 million).<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/sehk25062703372_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk25062703372_c.\"><\/object><a id=\"wp-block-file--media-2e09487a-696e-41bc-893c-8f32a0781ca3\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/sehk25062703372_c.pdf\">sehk25062703372_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/sehk25062703372_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-2e09487a-696e-41bc-893c-8f32a0781ca3\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based GenFleet Therapeutics (Shanghai) Inc. has submitted its initial public offering (IPO) application to the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":36247,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,1682,72],"class_list":["post-36245","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-genfleet-therapeutics","tag-ipo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GenFleet Therapeutics Files for Hong Kong IPO Amid KRAS Inhibitor Success - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based GenFleet Therapeutics (Shanghai) Inc. has submitted its initial public offering (IPO) application to the Main Board of the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=36245\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenFleet Therapeutics Files for Hong Kong IPO Amid KRAS Inhibitor Success\" \/>\n<meta property=\"og:description\" content=\"China-based GenFleet Therapeutics (Shanghai) Inc. has submitted its initial public offering (IPO) application to the Main Board of the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=36245\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-30T06:58:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-30T06:58:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/3001.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36245#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36245\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GenFleet Therapeutics Files for Hong Kong IPO Amid KRAS Inhibitor Success\",\"datePublished\":\"2025-06-30T06:58:06+00:00\",\"dateModified\":\"2025-06-30T06:58:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36245\"},\"wordCount\":226,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36245#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/3001.webp\",\"keywords\":[\"Cancer\",\"GenFleet Therapeutics\",\"IPO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36245#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36245\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=36245\",\"name\":\"GenFleet Therapeutics Files for Hong Kong IPO Amid KRAS Inhibitor Success - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36245#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36245#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/3001.webp\",\"datePublished\":\"2025-06-30T06:58:06+00:00\",\"dateModified\":\"2025-06-30T06:58:07+00:00\",\"description\":\"China-based GenFleet Therapeutics (Shanghai) Inc. has submitted its initial public offering (IPO) application to the Main Board of the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36245#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36245\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36245#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/3001.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/3001.webp\",\"width\":1080,\"height\":608,\"caption\":\"GenFleet Therapeutics Files for Hong Kong IPO Amid KRAS Inhibitor Success\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36245#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenFleet Therapeutics Files for Hong Kong IPO Amid KRAS Inhibitor Success\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GenFleet Therapeutics Files for Hong Kong IPO Amid KRAS Inhibitor Success - Insight, China&#039;s Pharmaceutical Industry","description":"China-based GenFleet Therapeutics (Shanghai) Inc. has submitted its initial public offering (IPO) application to the Main Board of the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=36245","og_locale":"en_US","og_type":"article","og_title":"GenFleet Therapeutics Files for Hong Kong IPO Amid KRAS Inhibitor Success","og_description":"China-based GenFleet Therapeutics (Shanghai) Inc. has submitted its initial public offering (IPO) application to the Main Board of the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor.","og_url":"https:\/\/flcube.com\/?p=36245","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-30T06:58:06+00:00","article_modified_time":"2025-06-30T06:58:07+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/3001.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=36245#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=36245"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GenFleet Therapeutics Files for Hong Kong IPO Amid KRAS Inhibitor Success","datePublished":"2025-06-30T06:58:06+00:00","dateModified":"2025-06-30T06:58:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=36245"},"wordCount":226,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=36245#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/3001.webp","keywords":["Cancer","GenFleet Therapeutics","IPO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=36245#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=36245","url":"https:\/\/flcube.com\/?p=36245","name":"GenFleet Therapeutics Files for Hong Kong IPO Amid KRAS Inhibitor Success - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=36245#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=36245#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/3001.webp","datePublished":"2025-06-30T06:58:06+00:00","dateModified":"2025-06-30T06:58:07+00:00","description":"China-based GenFleet Therapeutics (Shanghai) Inc. has submitted its initial public offering (IPO) application to the Main Board of the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=36245#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=36245"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=36245#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/3001.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/3001.webp","width":1080,"height":608,"caption":"GenFleet Therapeutics Files for Hong Kong IPO Amid KRAS Inhibitor Success"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=36245#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GenFleet Therapeutics Files for Hong Kong IPO Amid KRAS Inhibitor Success"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/3001.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36245"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36245\/revisions"}],"predecessor-version":[{"id":36248,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36245\/revisions\/36248"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/36247"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36245"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}